According to official news, Agora announced that starting from April 3, 2026, it will gradually stop the issuance and support of AUSD on the Injective network. According to the latest adjustments, no new AUSD will be minted on Injective from today, and AUSD held on this network will no longer earn any rewards. However, users can still redeem AUSD at a 1:1 value, and the redemption window will last until September 28, 2026. This adjustment only applies to the Injective network and does not affect the operation of AUSD on other chains.
Regarding the redemption process, Agora stated that its clients can complete the operation through their account contacts. Users only need to send AUSD on Injective to the official channel, and the platform will assist in converting it to AUSD on the user-specified chain or exchanging it for US dollars and other supported stablecoins. The official emphasized that September 28, 2026, is the standard redemption deadline, and after that, remaining assets can still be processed, but may require additional KYC verification processes and related fees.
Agora pointed out that this decision stems from its regular evaluation mechanism for multi-chain deployment, with key considerations including actual usage, ecosystem health, and infrastructure costs. After a comprehensive assessment, Agora decided to strategically shrink the AUSD business on the Injective network to optimize resource allocation and improve overall operational efficiency.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


Key Takeaways: New Governor Hyun-Song Shin supports CBDCs and tokenized deposits but omits stablecoins from his agenda. The…


Key Takeaways The Bank of Japan (BOJ) is pioneering the use of blockchain for central bank reserve settlements,…

Key Takeaways The Bank of Japan (BOJ) is leading the way as the first G7 member to explore…

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.









Key Takeaways: New Governor Hyun-Song Shin supports CBDCs and tokenized deposits but omits stablecoins from his agenda. The…
Key Takeaways The Bank of Japan (BOJ) is pioneering the use of blockchain for central bank reserve settlements,…
Key Takeaways The Bank of Japan (BOJ) is leading the way as the first G7 member to explore…
Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.